
Happening now: our #AACR23 presentation on the compelling evidence supporting targeted inhibition of DHX9 as a novel therapeutic modality in MSI-H colorectal cancer. Click here to learn more: https://t.co/ahXTcQRMuA

Accent is developing oncology-focused, small molecule therapies in the emerging field of RNA modification.

Happening now: our #AACR23 presentation on the compelling evidence supporting targeted inhibition of DHX9 as a novel therapeutic modality in MSI-H colorectal cancer. Click here to learn more: https://t.co/ahXTcQRMuA

If you're at the 2023 @GordonConf on RNA Editing this week, you won't want to miss our poster "Discovery of Small Molecule Inhibitors of #ADAR1"!

Thoughtfully building and scaling compound management is essential to efficient, highly-integrated small molecule #drugdiscovery and development - learn more about our approach as shared at #SLAS2023

If you'll be at #SLAS2023, don't miss the chance to see two exciting posters from #TeamAccent!

Congratulations to our founder, Chuan He, on being named a #WolfPrize2023 Laureate in Chemistry for "discovering reversible RNA methylation and its role in the regulation of gene expression"!
Congratulations to Chuan He, 2023 Wolf Prize laureate in Chemistry! @UChiChemistry @UChicago

We are delighted to welcome Serena Silver to #TeamAccent as our Vice President of Biology! accenttx.com/team-accent/ #lifesciences #Leaders

Congratulations to our scientific advisor and thought partner, Professor Karen Allen!
The DBC is pleased to announce that Prof. Karen Allen of Boston University is the winner of the inaugural Abeles and Jencks Award for the Chemistry of Biological Processes for 2022! divbiolchem.org @BUChemistry @allenlab @AmerChemSociety

DYK that #TeamAccent is proudly 50% female? Today our hardworking team celebrates #WomenInScience Day and all of the amazing, difference-making #WomenInSTEM!

Today, #WorldCancerDay, and every day, we join the @uicc in promoting greater understanding and recognition of the inequities in cancer care around the globe. Together, we must #CloseTheCareGap.

We are thrilled to welcome Stephen Blakemore to #TeamAccent as our Vice President of Translational Medicine! accenttx.com/team-accent/ #lifesciences #leaders

Congratulations to our co-founder and thought partner, Chuan He!
Introducing Chuan He, the new Editor-In-Chief of ACS Chemical Biology! Read about his vision for the journal, his current research interests, and his advice for young scientists here- go.acs.org/dq

Coming up! Our Vice President of Molecular Discovery, Ann Boriack-Sjodin, presents at the 4th Annual @RNA_TDD Summit on December 9th! accenttx.com/news-and-events…

We are pleased to entrust our #METTL3 program to the innovative team at @IpsenGroup and delighted to share the news of this partnership! #RMPs #RNAModification accenttx.com/press-releases/…

Our issue this week includes work by Robert A. Copeland, Steve Bourgault, Junichi Taira, Shogo Nakano, Sohei Ito, @clvizcarra and more. Check out issue 29 now at pubs.acs.org/toc/bichaw/60/2… @accent_tx @ChimieUqam @kyutech @Barnard_Chem

If you're looking for inspiration on this #InnovationWednesday - you won't want to miss "Chance Favors the Perplexed Mind" out today in @BiochemistryACS from our own Bob Copeland! pubs.acs.org/doi/10.1021/acs…

A "must add" for your holiday weekend reading list - our own Bob Copeland's Expert Opinion on the importance and evolution of the drug-target residence time model! Happy #PublicationFriday! doi.org/10.1080/17460441.202…